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Background: Right ventricular (RV) adaptation to acute and
chronic pulmonary hypertensive syndromes is a significant
determinant of short- and long-term outcomes. Although
remarkable progress has been made in the understanding of RV
function and failure since themeeting of theNIHWorking Group on
Cellular and Molecular Mechanisms of Right Heart Failure in 2005,
significant gaps remain atmany levels in the understanding of cellular
and molecular mechanisms of RV responses to pressure and volume
overload, in the validation of diagnostic modalities, and in the
development of evidence-based therapies.
Methods: A multidisciplinary working group of 20 international
experts from the American Thoracic Society Assemblies on
Pulmonary Circulation and Critical Care, as well as external content
experts, reviewed the literature, identified important knowledge gaps,
and provided recommendations.
Results: This document reviews the knowledge in the field of RV
failure, identifies and prioritizes the most pertinent research gaps,
and provides a prioritized pathway for addressing these preclinical
and clinical questions. The group identified knowledge gaps and
research opportunities in three major topic areas: 1) optimizing
the methodology to assess RV function in acute and chronic
conditions in preclinical models, human studies, and clinical
trials; 2) analyzing advanced RV hemodynamic parameters
at rest and in response to exercise; and 3) deciphering the
underlying molecular and pathogenic mechanisms of RV
function and failure in diverse pulmonary hypertension
syndromes.
Conclusions: This statement provides a roadmap to further
advance the state of knowledge, with the ultimate goal of
developing RV-targeted therapies for patients with RV failure
of any etiology.
Keywords: right ventricle; pulmonary hypertension; pulmonary
embolism; acute respiratory distress syndrome; pulmonary
circulation
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Overview
Right ventricular (RV) function is the single
most important prognostic determinant of
survival in various forms of pulmonary
hypertension (PH). Significant progress
has been made since improving the
understanding of RV function and failure
was identified in 2005 as a major area of
need in the field; however, many knowledge
gaps remain. A better understanding of
the mechanisms of RV adaptation and
maladaptation to pulmonary hypertensive
syndromes will advance the field toward
the goals of defining physiological and
pathophysiological RV responses,
identifying biomarkers of RV function, and
developing RV-directed therapies. This
document lays the framework for addressing
knowledge gaps in clinical and basic RV
research and for identifying research
opportunities and pathways forward.
d The task force defined RV failure (RVF) as
a complex clinical syndrome characterized
by insufficient delivery of blood from the
RV in the setting of elevated systemic
venous pressure at rest or exercise.
d RVF is a heterogeneous syndrome.
Multiple RVF phenotypes exist.
d The task force identified multiple
knowledge gaps and research
opportunities in the field. The four major
research priorities that should be
addressed in the next 5 years are:
1. Enhancing mechanistic
understandings of adaptive versus
maladaptive RV responses to
pulmonary vascular load. This
includes, but is not limited to,
understanding the roles of fibrosis,
angiogenesis, inflammation and
metabolic shifts. Genetic and
epigenetic contributions to successful
adaptation need to be identified.
2. Deriving and validating a series of
plasma and/or imaging biomarkers
(by echocardiography and cardiac
magnetic resonance imaging) for
accurate evaluation of RV function,
perfusion, and RV–pulmonary
vascular coupling and to serve as
endpoints in clinical trials.
3. Developing and validating novel animal
models and improving existing models
of RVF in the setting of increased
pulmonary vascular load to provide a
platform for better understanding
mechanisms of RVF and for testing
novel RV-directed therapies.
4. Developing novel therapies aimed at
targeting RV myocardial contractility
(e.g., calcium sensitizing agents) as a
critical area of need that would be
expected to improve patient outcomes.
d Increased availability to and methods to
study human RV tissue will be critical in
addressing these research priorities and
in advancing the field.
Introduction
RV failure (sometimes also referred to
as “right heart failure”) is increasingly
recognized in acute and chronic pulmonary
hypertensive syndromes, and RV adaptation
to these disease states is a significant
determinant of short- and long-term
outcomes (1–5). An estimated 70 million
individuals in the United States may have
abnormal RV function (3, 4, 6–10).
Thirteen years have passed since the
initial meeting of the NIH Working Group
on Cellular and Molecular Mechanisms
of Right Heart Failure (1). Although
remarkable progress has been made in the
intervening period, significant gaps remain
at many levels in the understanding of
cellular and molecular mechanisms of RV
responses to pressure and volume overload,
in the validation of diagnostic modalities,
and in the development of evidence-based
therapies (1, 2, 11, 12). RV function is
the single most important prognostic
determinant of survival in pulmonary
arterial hypertension (PAH) (3) as well as
in multiple highly prevalent chronic heart
and lung diseases (4, 6, 7, 10); however, no
consensus exists regarding the definition of
RV failure (RVF). This deficiency reflects
in part the current paucity of clinically
available, specific biomarkers reflecting RV
function. In addition, targeted therapy for
RVF remains elusive. Most importantly,
factors determining transition from
adaptive (or compensated) to maladaptive
(or decompensated) RV remodeling and
predictors of RVF remain unknown.
The purpose of this document is to:
1. Comprehensively elucidate the current
understanding of RV function and its
assessment in healthy individuals and
those with preclinical, acute, and
chronic diseases;
2. Identify major knowledge gaps; and
3. Outline specific strategies for addressing
these gaps.
We sought to address these objectives
across three topic domains:
Topic Domain 1
Optimizing the methodology to assess RV
function in acute and chronic conditions in
pre-clinical models, human studies, and
clinical trials. This provides the basic
framework for optimally assessing RV
morphology, function, and failure in animal
models of disease and in humans.
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Topic Domain 2
Analyzing advanced RV hemodynamic
parameters at rest and in response to
exercise. Recommendations are provided
for improving the understanding of RV
contractile and diastolic function as well
as RV–pulmonary vascular coupling in
response to load and exercise in both
preclinical and clinical models. This will
further our understanding of RV dynamic
function adaptation and functional reserve
and will establish optimal measures to be
used in clinical assessment of the RV.
Topic Domain 3
Deciphering the underlying molecular
and pathogenic mechanisms of RV function
and failure in diverse PH syndromes.
Identifying pathophysiologically relevant
adaptive and maladaptive processes (e.g.,
angiogenesis, inflammation, fibrosis) in
preclinical models will set the stage for
targeted therapy to be tested in clinical trials.
Findings and recommendations
generated from these topic domains address
the overarching questions and cross-cutting
themes listed in Table 1.
The intended audience of this report
includes basic, translational, and clinical
researchers in the fields of pulmonary
circulation, cardiovascular medicine,
respiratory and critical care medicine, research
funding organizations, health policy experts,
and pharmaceutical and device industries.
Methods
A working group of international experts
from the American Thoracic Society (ATS)
Assemblies on Pulmonary Circulation and
Critical Care (18 ATS members and two
external content experts) was convened,
which included basic, translational, and
clinical researchers with expertise in a
broad range of areas within adult
pulmonary and critical care medicine,
cardiovascular medicine, cardiothoracic
surgery, physiology, and pathology. The
scope of the project was reviewed and
approved by the ATS. Potential conflicts
of interest were disclosed and managed
in accordance with the policies and
procedures of the ATS. No unresolvable
conflict of interest was identified.
This task force met twice in person (ATS
2015 for a full-day workshop and ATS 2016
for a 2-hour summation) and multiple times
in between by teleconference. Major focus
areas were developed by semistructured
systematic review of the literature, expert
opinion, and consultation. During the initial
workshop, goals and ground rules guiding the
work group were established. Subjects to be
discussed were suggested by the steering
committee and agreed on by the group.
Presentations by content experts weremade in
each of the three topic domains, followed by
group discussion aimed at defining key areas
of consensus and disagreement. Current
knowledge state summaries were then
developed and rigorously analyzed by the
entire workgroup and in focus area subgroups.
Structured knowledge gap analyses were
conducted in all three topic domains.
The draft was circulated to the task
force members with revisions at each step.
Consensus was achieved through moderated
discussion. Data cloud document
management was used to coordinate version
control and integrate components from the
subgroups. The final report was peer reviewed,
approved by the leadership of each of the
sponsoring Assemblies, and ultimately
approved by the ATS Board of Directors.
Definition, Development, and
Staging of RVF
The task force defined RVF as a complex
clinical syndrome characterized by insufficient
delivery of blood from the RV and elevated
systemic venous pressure at rest or exercise.
RVF occurs as a consequence of 1)
alterations in preload; 2) changes in RV
mechanics, lusitropy, and/or contractility;
or 3) increases in afterload (Figure 1A).
Similar to left ventricular (LV) failure,
chronic RVF occurs in four distinct stages
(Figure 1B). Some investigators use the
term “RV dysfunction” to indicate
structural RV changes in the absence of
functional alterations. In this statement,
we avoid this term, because such a
constellation would qualify as “RV failure”
according to the definition provided above.
Although frequently progressive in
character, with appropriate intervention(s),
progression may stop at any of these stages
or even be reversible. On the other hand,
acute decompensation may develop at any
of the four RVF stages. Once acute RVF
develops, patients may deteriorate or
stabilize (Figure 1C). Several clinically
relevant modifiers of RV function exist
(Figure 2A). PH is a syndrome commonly
associated with RVF and is a prime
example of how the RV responds to
chronically elevated afterload (Figure 2B).
With increases in pulmonary artery
pressure (PAP), the RV exhibits
compensatory mechanisms that include
homeometric and heterometric adaptation
as well as neurohormonal activation (2, 13).
Adaptive RV hypertrophy (RVH) develops.
It is believed, although not fully proven,
that once the RV’s compensatory
mechanisms are exhausted (purportedly as
a result of transition from adaptive to
maladaptive RVH), RVF develops. Genetic
predispositions and early life events are
putative modifiers of the RV compensatory
response (Figure 2B). Figure 3 highlights
key aspects of RVF pathophysiology
addressed in this research statement.
Topic Domain 1: Optimizing
the Methodology to Assess
RV Function in Acute and
Chronic Conditions in
Preclinical Models, Human
Studies, and Clinical Trials
Normative Indices of RV Morphology
and Function
Rationale. Despite the high prevalence of
RVF in the United States and throughout
the world (3, 4, 6–10), there are no
Table 1. Overarching Questions and Cross-Cutting Themes Addressed in This
Document
1. What are the hallmarks of acute and chronic RVF?
2. What are the mechanisms underlying transition from adaptive to maladaptive RV
function?
3. What are clinically relevant endpoints in RV research, and are they accurately assessed
and validated?
4. What are currently available tools in RV research, and what are their limitations?
5. What are the current knowledge gaps in research assessing acute and chronic RV failure,
and what are the suggested remedies?
Definition of abbreviations: RV = right ventricular; RVF = right ventricular failure.
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Chronic RHF
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Deterioration
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Arrhythmia Ischemia
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At risk of PAH
and/or RVF
Genetic predisposition
Enviromental
Endogenous
Primary
prevention
Secondary
prevention
Patients with
established
pulmonary vascular
disease
May represent
acute, chronic, or
acute on chronic  RVF
Specialized intervention:
transplant/septostomy
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A
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Figure 1. Etiologies and stages of right ventricular failure (RVF). (A) RVF occurs as a consequence of alterations in preload, changes in mechanics and/or
decreases in contractility, or increases in afterload. (B) Classification of RVF according to stages of development in keeping with the recent classification
of the American College of Cardiology Foundation/American Heart Association Task Force for Heart Failure (298, 299). Note that stages are not static
and that stages C and D are potentially reversible with normalization or significant decrease in pulmonary vascular resistance (e.g., after pulmonary
endarterectomy or lung transplantation) (300, 301). Symptomatic RVF (stage C) is usually managed pharmacologically, whereas refractory RVF (stage D)
often requires specialized interventional or surgical measures. Preventive measures may be applied at any of the different stages of RVF. Decompensation
may occur at any stage. (C) Cycle of acute on chronic decompensation of RVF. Acute decompensation is usually provoked by one or more precipitating factors
(e.g., infection, pulmonary embolism, bleeding disorders) or by progression of the underlying disease (112). Patients frequently deteriorate and enter a
vicious cycle of hypotension, ischemia, and decreased pump function or may stabilize and revert to more or less stable chronic RVF. However, mortality
after hospital discharge remains high (35% at 12 mo [112]). PAH = pulmonary arterial hypertension; RHF = right heart failure.
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well-established biologic or clinical
determinants of RV structure and function.
Thus, there remains significant scientific
and clinical justification for studying the
structure and function of the RV in greater
detail during health. Establishing normative
values will enhance our understanding of
subclinical changes in disease and may
allow for early/preventative treatment.
Unlike the LV, the thin-walled, compliant
RV has difficulty accommodating increases
in afterload, and even small increments or
fluctuations in afterload may lead to
adverse RV sequelae (13, 14), particularly
if the increase in PAP is rapid. There is,
however, great variability in the clinical
trajectory of patients, who often present at
later stages of disease, when RVF is overt
(Figure 1B). Furthermore, observations
from population-based cohorts may
provide insight into important mechanistic
pathways generalizable to RVF, regardless
of etiology. Finally, targeting patients before
the development of significant RVF may be
more successful than instituting therapy
after advanced disease is established.
Current state of knowledge. An ideal
RV metric would be sensitive enough to
capture subtle cardiac structural changes,
reliable, reproducible, inexpensive, and
easily obtained. It would be validated across
settings and in different populations.
Echocardiography can qualitatively assess
RV function and can be used to measure
ventricular volumes and wall motion.
However, quantification requires geometric
assumptions, and these are hindered by the
crescentic, thin-walled shape of the normal
RV and also by subject characteristics (e.g.,
body habitus), which could introduce bias.
In contrast, cardiac magnetic resonance
imaging (CMR) is a fundamentally safe and
reliable modality from which quantitative
data regarding RV size, function, and
remodeling are acquired rapidly with
limited artifact. However, it is relatively
expensive in some settings and not
universally available.
Measurement of RV ejection fraction
(RVEF) and RV mass and volumes by CMR
is highly accurate and reliable in normal
subjects and in those with RV or LV failure
(15–18). Thus, CMR is the standard of
measuring imaging technique for RV
assessment (although echocardiography is
more practical in the unstable patient
because it can be performed at the bedside).
RVEF has been identified as a key
determinant of outcome in RVF regardless
of etiology, including PH due to LV failure
(group 2 PH) or advanced lung disease
(group 3 PH), and PAH (4, 6, 7) (group 1
PH). RVEF predicts outcome in PAH, and
changes in RVEF mediate improvements
in survival with disease-specific therapy,
making it currently the most reliable
surrogate RV endpoint (3, 19–22). Several
other imaging techniques have been shown
to measure RV function and predict
outcome (e.g., tricuspid annular plane
systolic excursion [TAPSE], speckle-
tracking for strain imaging, three-
dimensional [3D] echocardiography,
fluorodeoxyglucose–positron emission
tomography [PET]) but are less well
validated, especially in health or early
disease (23–27).
Current knowledge gaps. Normative
values for RV size and function have been
derived from the MESA-RV (Multi-Ethnic
Study of Atherosclerosis–Right Ventricle)
Endogenous modifiers (e.g., sex,
age, race, genome)
Exogenous modifiers (e.g., early
life events, toxins)
•
•
 Genetic, genomic, epigenetic,
molecular changes
Normal
Response
to therapy
Stage
RVF classifier
“In depth” phenotypes
(molecular imaging, perfusion,
“OMICS”)
Severity
(hemodynamics, RV dysfunction, VA coupling,
biomarkers [BNP, troponin], RV remodeling or fibrosis,
arrhythmia, systemic involvement)
Stability
(chronic vs. acute)
Functional class
(NYHA class, max VO2, VE/VCO2)
Adapted Maladapted
A
B
PVR
Ees/Ea
Ees
Cardiac index at rest
Right ve
ntricular
 volumeMP
AP
Figure 2. Classifiers and time course of right ventricular failure (RVF). (A) RV function is described
using several characteristics, such as stage and acuity, as well as functional class (either by New York
Heart Association [NYHA] classification or by cardiopulmonary exercise testing) and severity (using
hemodynamic characteristics, markers of RV function, ventriculoatrial [VA] coupling, imaging or
plasma biomarkers indicating RV remodeling, as well as presence or absence of arrhythmias [e.g.,
atrial fibrillation] and presence or absence of systemic involvement [e.g., liver congestion, renal
impairment]) (2, 128, 162). Response to therapy (e.g., treatment-responsive vs. refractory RVF)
is frequently used for classifying RV function as well. Novel classifiers and “deep” phenotyping
tools include imaging approaches aimed at assessing perfusion, metabolism, and/or fibrosis,
complemented by “omics” and “big data” approaches. (B) Time course of RVF development in the
setting of chronic pressure overload from pulmonary vascular disease. See Reference 128 for detailed
review of the supporting literature. Note that significant molecular and temporal heterogeneity exist in
RV adaptation and maladaptation to pressure overload, possibly determined by genetic, genomic,
epigenetic, and molecular changes due to endogenous and exogenous factors. For example, in
scleroderma-associated pulmonary arterial hypertension (PAH), end-systolic elastance (Ees) is lower
than in idiopathic PAH, and Ees/arterial elastance (Ea) decreases earlier than in other disease states
(170). Cardiac output/cardiac index decreases as a result of transition from adaptive to maladaptive
remodeling, because of either progression of the underlying disease or an additional insult. BNP =
brain natriuretic peptide; MPAP =mean pulmonary arterial pressure; PVR = pulmonary vascular
resistance. (B) Modified from Reference 302.
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e19
Study, the Framingham Heart Study, and
other cohorts (28–35). However, these
observations need to be validated 1) in
health and disease, 2) longitudinally, and
3) in other populations. Racial, ethnic and
socioeconomic differences need further
exploration (28, 36, 37). Normal values for
RV function are needed for physiological
modifiers of the normal RV in pregnant
subjects and athletes, and the effects of
processes such as puberty, menopause, and
aging merit study. The temporal evolution
with early life events (e.g., prematurity)
also requires further study (38–40). The
definition and relevance of subclinical RV
changes, and their role in the natural
history of RVF, are also incompletely
elucidated.
Recommendations/pathway for
progress. Several knowledge gaps exist,
which include a better understanding of the
normative indices of RV morphology and
function, the impact of key demographic
characteristics (age, sex, race/ethnicity,
and socioeconomic status) on the healthy
RV, RV development throughout the
life span, subclinical RV abnormalities,
cardiopulmonary interactions under stress,
and, finally, the impact of biventricular
interactions. Such studies should include
neonates and prematurely born babies,
especially because the latter are at risk
for developing RV abnormalities later in
life (38).
Optimization of RV Assessment in
Clinical Research
Rationale. Trials to detect differences in
clinical worsening or survival generally
require a substantial sample size, which can
be difficult to complete in rare diseases such
as PAH, especially when the intervention
being studied is added to background
therapy. A well-chosen RV surrogate
endpoint in clinical trials may facilitate trial
design, and ultimately drug approval,
because RVF is the leading cause of death
in PAH (3). An endpoint must be both
accurate and precise, as measurement error
can lead to bias and, therefore, erroneous
conclusions.
Current state of knowledge. A given
endpoint needs to satisfy a number of
criteria to serve as a surrogate for “hard”
clinical outcomes before incorporation into
clinical trials (41–43). It should be reliable,
integral to the disease causal pathway, and
targeted by the intervention of interest, and
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Figure 3. Concept figure of changes in right ventricular (RV) structural, functional, and
biochemical/molecular processes as the RV transitions from normal function to failure in the setting of
increased afterload. Afterload increases can be acute (e.g., in cases of pulmonary embolism or acute
respiratory distress syndrome) or chronic (e.g., in pulmonary arterial hypertension, pulmonary
hypertension from chronic heart or lung disease, or chronic thromboembolic pulmonary
hypertension). With progressive increases in RV afterload (top), RV size increases. In forms of chronic
afterload increases, RV hypertrophy develops. RV stroke volume, RV contractility, and RV–pulmonary
artery (PA) coupling are initially maintained (or even increased) but then progressively decrease. In
parallel, RV diastolic dysfunction and RV–left ventricular (LV) dyssynchrony develop. At a
molecular/biochemical level, these processes are accompanied by alterations in angiogenesis,
calcium handling, mitochondrial function, and sarcomere organization, as well as progressive
increases in inflammation, neurohormonal activation, fibrosis/collagen deposition, oxidative stress,
metabolic dysfunction, and cardiomyocyte apoptosis. Note that for didactic purposes, long-term
trajectories for all changes are shown as gradual increases or decreases, whereas in reality these
changes may exhibit fluctuations and not develop in a parallel manner. Topic domain 1 of this
research statement focuses on optimizing the methodology to assess RV function in acute and
chronic conditions in preclinical models, human studies, and clinical trials. Structural and functional
RV changes (shown in red, orange, and blue) are covered in topic domain 2; biochemical/molecular
processes (in green) are discussed in topic domain 3.
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be linked with a clinically important
outcome, such as survival. Finally, a
significant proportion of the treatment effect
(50–75%) on clinical outcome should be
explained by the effect of the intervention on
the surrogate endpoint. The requirements
for a disease surrogate are much more
stringent than for a correlate, and in fact
several long-held endpoints in PAH, such
as 6-minute-walk distance (6MWD) and
hemodynamics, are inadequate surrogates
for short-term events (44–48).
Current knowledge gaps. A number
of RV endpoints have been proposed,
including biomarkers (e.g., BNP [brain
natriuretic peptide] and troponin) as well as
metrics obtained from traditional and novel
imaging techniques (23–27, 49–52).
Although there is currently no consensus
on how to best measure RV function in
clinical trials, there is some evidence that
current PAH treatments may have unique
effects on the RV (criterion #2 for a
surrogate; as demonstrated in a limited way
with sildenafil and simvastatin and RV
mass, and with bosentan and RV stroke
volume [53–55]). Up-front combination
therapy with ambrisentan and tadalafil
reduced RV mass and NT-pro-BNP
levels and increased RV contractility as
measured by TAPSE or speckle-tracking
echocardiography in an open-label trial in
scleroderma-associated PAH (56, 57). Small
observational studies demonstrated that
worsening RV performance is associated
with poor outcomes independent of
pulmonary vascular resistance (3, 53, 58).
These observations, along with those that
demonstrated classic endpoints (e.g.,
6MWD and hemodynamics) to be
inadequate, suggest we may not fully
understand how currently approved PAH
treatments work (e.g., by targeting the
pulmonary circulation or the RV or
through other systemic effects) (59). The
study of patients with PH with a severe
RVF phenotype independent of the etiology
(i.e., WHO groups 1–5) may allow for
larger and faster trials; however, such an
approach has not yet been tested. CMR
is accurate, reproducible, and allows for
detecting small changes in RVEF (z3%)
in sample sizes that are modest. It is
considered the standard of measure for
RV morphology and function and has been
shown to be more cost saving in PAH drug
trials than echocardiography, as a result of
its lower measurement variability (60).
Although some investigators advocate that
CMR should be routinely incorporated into
clinical trials, wide-scale incorporation into
trials and ultimately clinical practice may
be limited in some centers by cost and
technical expertise.
Recommendations/pathway for
progress. Measurements of RV function
should be routinely incorporated into
observational studies and clinical trials in
pulmonary vascular disease, even if not as
the primary endpoint. Longer, time-to-event
clinical trials are now being conducted in
PAH using composite morbidity and
mortality endpoints (61, 62), which is the
ideal setting in which to validate potential
RV-based surrogate endpoints. The
validation of an RV surrogate in this setting
would contribute greatly to the feasibility of
smaller phase II trials to identify potentially
promising therapies from ineffective
ones. CMR has greater sensitivity and
reproducibility than ultrasound and thus can
rapidly detect an efficacy signal with a small
sample size in a short period of time,
potentially minimizing cost and avoiding
trial futility (60). However, its routine use in
clinical trials needs further validation.
Optimization of Animal Models of RVF
Rationale. Animal models of disease are
critical to understanding the physiology and
structural and molecular underpinnings
of the human conditions they attempt
to recapitulate. They facilitate therapy
discovery and safety evaluation. For RVF,
an animal model that recapitulates the
mechanisms and prognostic implications
of RVF in humans would minimize
requirements for human tissues, and new
understanding of molecular processes
driving failure would accelerate the
discovery and preclinical testing of potential
drugs for RVF.
Current state of knowledge. An ideal
RVF animal model would be reproducible
by individual investigators over time, as well
as reproducible across institutions. Such a
model would also be inexpensive, feature
relatively brisk disease development for
rapid knowledge acquisition, and, most
importantly, accurately represent
physiologic and molecular characteristics of
the human RVF phenotypes. Given the
varied clinical conditions resulting in
primary or secondary RVF, a single animal
model fulfilling all these criteria is unlikely
(63). Presently, there are several commonly
used animal models of RVF (Table 2), all
with limitations and none considered the
single “best” model. With the exception of
exposure to hypoxia and pulmonary artery
banding (PAB), which can be done in mice,
rats have been used predominantly, as they
most reliably reproduce the vascular lesions
characteristic of human PAH (64).
Pulmonary vascular lesions generated in
different models vary (64).
Current knowledge gaps. Whether the
development of RVF in these preclinical
models is purely a function of hemodynamic
overload or specific lung and systemic
vascular lesions in variousmodels is unknown.
PAB can be applied to both rats and mice and
does not elicit pulmonary vascular disease, but
it has technical limitations and variable effects
on the RV. The comparison of pure RV
pressure overload models (such as PAB)
versus pressure overload syndromes due to
pulmonary vascular disease (as induced by
monocrotaline or Sugen plus hypoxia)
suggests that the former model manifests
adaptive RVH and may be relevant to
congenital heart diseases (such as pulmonic
stenosis), whereas the latter may be more
reflective of the maladaptive RVH seen in
most patients with WHO group 1 PH (65).
However, it is believed, although not fully
proven, that decreased cardiac output (CO)
and maladaptive RVH can develop in this
model as well, depending on the degree and
duration of the banding (66). A need exists
for models of pure RV volume overload. The
role of alternative models of RVF, including
large animal models (67, 68) and transgenic
mouse models (69), needs to be defined
further.
Recommendations/pathway for
progress. We recommend matching the
animal model to the experimental question
asked. For instance, when the experimental
question involves the etiology of RV fibrosis,
monocrotaline or Sugen plus hypoxia may
be relevant. Alternatively, when studying
molecular mechanisms behind the
progression from compensated RVH to
RVF, PAB with various degrees and/or
durations of banding is preferable.
Corroboration of results in more than one
model strengthens experimental findings (70).
The RV Langendorff model is a useful
ex vivo model to assess RV inotropy
and lusitropy (71–73) and a useful
adjunct to in vivo assessments of the
RV, which are largely load dependent.
Large animal models of RV pressure
and volume overload (with and without
pulmonary vascular disease) will likely
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be very helpful in the latter stages of
preclinical testing of drugs and devices,
before use in humans. RV volume
overload could be generated by inducing
compromising tricuspid valve insufficiency.
The design of novel, translationally
relevant models is dependent on a
better molecular understanding of the
unique determinants of human RVF.
A better molecular understanding of
the basis for RVF may lead to improved
transgenic animal models or preference
for one of the existing models with
greater understanding of its implications.
In the absence of these data, we
recommend:
1. Correlation of findings from animal
models with human tissue.
2. Consideration of sex and age in animal
models of RVF.
3. Incorporation of right heart
catheterization (RHC) (thermodilution
and/or pressure–volume analyses
using high-fidelity conductance
catheters), echocardiography, and/or
CMR to measure CO, a marker of RV
function.
4. Combine CO measurements with
other functional measurements (e.g.,
TAPSE and RV dilatation with
echocardiography), RV volumes (CMR),
and/or ventriculoarterial coupling
(using pressure–volume loops).
Table 2. Commonly Used Animal Models of Right Ventricular Failure
Monocrotaline Hypoxia Sugen/Hypoxia PA Banding
Method Subcutaneous injection of
alkaloid monocrotaline
(40–60 mg/kg; lower
dose results in milder
phenotype)
Exposure to FIO2 10%
(or 0.5 atmospheric
pressure) for 3–5 wk
Subcutaneous injection of
VEGFR2 antagonist
Su54161 hypoxia (3
wk)1 room air (>4 wk)
Suture or clip around main
PA
RVSP, mm Hg 40–60 30–40 60–80 60–80
Cardiac output Depressed Maintained or slightly
depressed
Severely depressed Maintained or depressed
(depending on tightness
of band and duration of
banding)
RV histology Fibrosis, cardiomyocyte
hypertrophy, possibly
biventricular
myocarditis (conflicting
data on the latter)
Fibrosis (less than other
models), cardiomyocyte
hypertrophy
Fibrosis, cardiomyocyte
hypertrophy, apoptosis
Fibrosis, cardiomyocyte
hypertrophy
RV vascular effects Vascular inflammation,
decreased capillary
density
Capillary proliferation No angiogenesis,
decreased capillary
volume and density
Capillary volume and
density maintained or
slightly decreased
Type of RV remodeling Maladaptive Adaptive Maladaptive Adaptive or maladaptive
(depending on tightness
of band and duration of
banding)
Pulmonary vascular
effects
Yes Yes Yes No
Systemic effects Yes Yes Yes No
Sex of animal tied to
experimental
phenotype
Yes (less PH in females) Yes (less PH in females) Yes (better RV function in
females)
Yes (better RV function in
females)
What is being modeled? Inflammatory PAH and RV
dysfunction
Chronic hypoxia, high
altitude, some aspects
of chronic lung disease
Pulmonary vascular
endothelial cell injury
with uncontrolled
proliferation of
remaining cells
RV afterload increase
without pulmonary
vascular injury
Modifications of model Combination with
pneumonectomy or
aortocaval shunting to
result in pulmonary
vascular overflow and
more pronounced
remodeling
Extension of room air
exposure associated
with progressive
pulmonary vascular
remodeling and
afterload increase
Definition of abbreviations: PA = pulmonary artery; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; RV = right ventricle; RVSP = right
ventricular systolic pressure; VEGFR2 = vascular endothelial growth factor receptor 2.
PH development is usually more pronounced in younger animals. Data from References 64, 65, 81, 264–279.
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Although optimization of animal
models of RVF is of utmost importance in
the field, these efforts should be paralleled
by the development of new in vitro
technologies, such as a “heart on a chip”
approach and/or cardiomyocytes or cardiac
endothelial cells differentiated from
human-PH induced pluripotent stem
cells. Such models could be used to study
RV cardiomyocyte–endothelial cell
interactions, screen drugs, and identify
novel signaling pathways.
Animal Models for RVF in Group 2
and 3 PH
Rationale. The majority of PH cases
worldwide are due to diseases such as
chronic LV and lung disease, sleep-
disordered breathing, or high altitude
exposure (group 2 and 3 PH) (74–76).
Treating the underlying condition is
typically the goal; however, a significant
number of patients may develop RVF, and
there has been considerable interest in
better understanding the mechanisms of
RVF in affected individuals. Therefore,
there is a need for adequate animal models
of RVF resulting from group 2 and 3 PH.
Current state of knowledge. RVF
generally does not develop in rodent models
of hypoxia exposure but is present in the
hypoxic newborn calf (77). In patients with
chronic lung disease, the development of
PH and/or RVF is not strictly linked to
chronic hypoxia but may also develop
because of hypercapnia, neurohormonal
alterations, comorbid cardiovascular
disease, and pulmonary vascular
obstruction and obliteration (78). Rodents
with Sugen- or cigarette smoke–induced
emphysema as well as bleomycin- or
adenoviral TGF-b–induced pulmonary
fibrosis may exhibit RVH but do not exhibit
significant RVF (79–83).
In models of LV disease, RVF may
develop as an integral part of a global cardiac
dysfunction (e.g., doxorubicin-induced
biventricular failure) (84). In addition,
isolated damage to the LV can directly
impair RV function (85), even in the
absence of PH (86). Development of
secondary PH in models of LV failure
induced by transverse aortic constriction is
little studied. Indeed, a significant degree of
lung vascular remodeling, PH, and RVF can
develop as soon as 4 weeks after transverse
aortic constriction in mice (87), suggesting
this may be a model of combined pre- and
postcapillary PH. Combined pre- and
postcapillary PH and RVF in the setting
of mitral stenosis or heart failure with
preserved ejection fraction may be more
aptly represented by a model of pulmonary
vein banding (reported in swine [88],
although with technical limitations for
mechanistic studies). A model of PH due to
LV diastolic dysfunction using Su5416
administration in obese ZSF1 rats has
recently been published; this model exhibits
moderate PH, but no overt RVF (89).
Similarly, AKR/J mice fed with a high-fat
diet develop increased LV end-diastolic
pressure and biventricular hypertrophy, but
it is unknown if they develop RVF (90). As
in patients, animal models may require
substantial time to develop RVF; this
feature may be overlooked because of cost
and time constraints, as well as arbitrary
requirements by animal care committees
that animals be killed if they become ill.
Clinically relevant surrogate endpoints
of failure to thrive (e.g., weight loss or
decreased oral intake) may occur before
overt RVF develops in these models.
Current knowledge gaps. Mechanisms
of RVF development in group 2 and
3 PH are multifactorial, but the relative
contributions of the various causes have not
yet been fully elucidated and are difficult to
mimic in small or large animals. Whether
treating RVF would translate to improved
clinical outcomes is currently unknown,
particularly as PAH medications have
largely been found to be ineffective or
harmful in patients with group 2 and 3 PH.
Recommendations/pathway for
progress. A better understanding of RV
function in patients with group 2 or 3 PH
will be critical for understanding the human
disease and for optimizing animal models.
Therefore, clinical studies should carefully
phenotype patients with RVF from these
syndromes, and studies should explore
whether treating RVF improves clinically
relevant outcomes. “Multiple hits” rather
than a “single hit” likely contribute to
human disease, and such multifactorial
etiologies should be considered in animal
models (89). Ultimately, even though the
“perfect” animal model may not ever
exist, the development of animal models
mimicking group 2 and 3 PH with
significant RVF would be a major
milestone. Isolated cardiomyocytes may
allow for mechanistic investigations of
specific pathways. Animal studies of group
2 or 3 PH should be of sufficient duration
to detect RVF. Ideally, more sophisticated
RV endpoints including BNP levels, CO
(measured by RHC and Doppler), and
formal assessment of RV size and function
should be incorporated. Studies in humans
should focus on deep phenotyping and
ideally involve the study of RV tissues.
RV Responses to Pulmonary
Embolism and Acute Respiratory
Distress Syndrome
Rationale. Both pulmonary embolism (PE)
and acute respiratory distress syndrome
(ARDS) cause relatively acute PH and RV
injury; the ensuing RVF results in significant
morbidity and mortality in both conditions.
Causes of RV injury in both scenarios
include increased afterload from PH and
impaired subendocardial RV perfusion
(91–94).
Current state of knowledge. Rapid
increases in PAP and PVR, as occur in
PE and ARDS, are poorly tolerated, and
the RV will fail and develop conduction
abnormalities that would not occur if the
pressure increased slowly, allowing time for
the development of compensatory RVH.
Both large PE and severe ARDS result in
uncoupling of the RV from the pulmonary
circulation (defined and discussed in
ASSESSMENT OF RV–PA COUPLING), and
subsequent inefficient forward flow. The
primary insult with PE comes from
macrovessel occlusion, whereas ARDS
results from microvessel occlusion with
widespread but heterogeneous alveolar
consolidation and elements of acute
hypoxic pulmonary vasoconstriction.
Both conditions shift the pulmonary
vasoconstrictor–dilator balance toward
an increase in afterload and result in
chemokine and cytokine release,
recruitment of inflammatory cells, and
production of reactive oxygen species
(95–101). LV diastolic dysfunction
(i.e., stiffness) may arise after acute PE and
persist despite PH resolution (102–104)
but likely is not a main contributor to
symptoms. Approximately 4% of acute PE
survivors develop chronic thromboembolic
PH (CTEPH) (105), making this one of the
most common forms of PH. Uniquely,
CTEPH has a high index of recovery after
intervention.
Current knowledge gaps. Although
RVF is an independent cause of increased
mortality in ARDS (106), the impact of RVF
prevention or treatment on prognosis in
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ARDS is unknown (107). Prone positioning
improves survival and RV function in
severe ARDS (108, 109); however, the
optimal methods and modes of ventilation,
as well as the roles of inotropic support,
varying levels of sedation, and paralysis to
protect the RV and limit RVF in patients
with ARDS all remain poorly studied.
Whether prone positioning is indicated
in cases of RVF independent of decreases
in PaO2/FIO2 remains to be evaluated as
well. Despite extensive research on the
mechanisms promoting lung injury and
pulmonary vascular dysfunction in ARDS,
no specific and effective targeted therapies
have emerged. For PE, the role of catheter-
directed fibrinolysis (vs. standard
anticoagulation) for intermediate-risk PE
requires large-scale randomized controlled
trial investigation (110). Significant gaps
exist in understanding the best ways to
support the failing RV during these
relatively acute RVF syndromes. The
optimal intravenous inotrope for clinical
use has not been identified. In animal
models of chronic RVH, dobutamine
appears superior for acute RV support
(111), but it is unclear if this also pertains to
acute RVF. Although use of inotropes in
RVF in the face of PAH identifies a patient
cohort at high risk (46%) of in-hospital
mortality, it is unclear if this is a mere
reflection of the severity of the underlying
condition rather than an inotrope effect per
se (112). It is also uncertain how best to
prevent secondary inflammatory RV injury
from PE and ARDS. Modulating LV
stiffness in resuscitation remains unstudied
for both conditions (102–104). Knowledge
about vasoconstrictor–vasodilator
balance, platelet hyperreactivity, and
coagulation–fibrinolytic balance has not
been adequately translated into early-phase
clinical trials. Mechanisms of development
of CTEPH after acute PE are incompletely
understood and need further study.
Recently developed rat and piglet models
(113–115) will facilitate such studies.
Recommendations/pathway for
progress. We recommend developing robust
and translationally applicable animal
models, designing RV-focused outcome
studies to assign risk in large cohorts, and
performing RV-focused randomized
controlled trials, particularly at the phase I
stage. Strategies aimed at understanding
common mechanisms of lung injury caused
by precapillary pulmonary vascular
occlusion associated with PE and/or ARDS
need to be identified. Goals should include
identifying optimal mechanisms of
enhancing CO while supporting systemic
vascular tone. This should include studies
modulating the b-adrenergic receptor in
RV cardiomyocytes as well as studies of
mechanical devices. In addition, this should
include the unraveling of cause and effect
interplay between small vessel occlusion by
cells and vasospasm and inflammatory
processes that can cause RV injury directly
and indirectly. The roles of disordered
coagulation, platelet activation, neutrophil-
derived networks, and regulation of
fibrinolysis need to be defined. For both PE
and ARDS, existing evidence raises the
hypothesis of a secondary inflammatory hit
to the RV, initiated by either direct injury
(e.g., shear stress or ischemia) or as
collateral damage from systemic
inflammation (116). The importance and
magnitude of effect of this secondary hit
require quantitative study. Priorities should
focus on producing translatable knowledge
in the laboratory and in clinical trials to
enhance the pipeline of new therapies for
both conditions. In addition, better data are
required to determine the optimal duration
of therapy. Guidelines should be developed
to assess whether and when RV function
should be assessed in patients who recover
from acute PE or ARDS. Investigating
whether CTEPH surveillance in survivors
of a documented PE improves outcomes is
therefore indicated. Mechanistic and
therapeutic preclinical studies in recently
developed CTEPH animal models will
provide further knowledge that can be
harnessed to improve outcomes of patients
with CTEPH.
Differences between Acute and
Chronic RV Responses
Rationale. Although identifying cellular and
molecular mechanisms that underlie
successful adaptation of the RV to chronic
stress can lead to efforts to prevent RVF in
patients with chronic RV pressure overload
(RVPO), this may also lead to strategies that
improve outcomes of acute PH. Similarly, a
better understanding of mechanisms of
acute RVF may lead to treatment strategies
for chronic RVF. For example, a detailed
knowledge of the mechanisms leading
to—or protecting against—myocardial
apoptosis in the acute setting could
improve the management of patients
suffering from both acute and chronic RVF.
Current state of knowledge. Acute
RVPO causes wall stress, exhaustion of
cardiomyocyte energy resources, impaired
calcium handling, release of
proinflammatory chemokines and
cytokines, inflammatory cell infiltration,
and generation of toxic reactive oxygen and
nitrogen species, all of which contribute to
cardiomyocyte death within hours or days
and loss of pump function (96, 98, 100,
101). In contrast, chronic RVPO triggers
a slower and more or less successful
adaptation to pressure overload (96, 117),
including complex alterations in energy
metabolism (generally away from fatty acid
oxidation [FAO] toward uncoupled
glycolysis and carbohydrate oxidation) as
well as hypoxemia, ischemia, inflammation,
and oxidative stress (1, 2, 13, 118, 119).
These changes are accompanied by
macroscopic and microscopic structural
remodeling of the myocardium and cardiac
microcirculation. The remodeling of
chronic RVPO includes cardiomyocyte
hypertrophy and, in case of unsuccessful
adaptation, fibrosis and capillary rarefaction
(65). Failure of compensatory mechanisms is
believed to trigger transition from adaptive to
maladaptive RVH, with ischemia considered
a major contributor (65, 120, 121).
Current knowledge gaps. It is likely that
changes in metabolism vary among forms of
RVF. For example, FAO is increased in PAB
(and inhibiting FAO is beneficial to RV
function) (122); conversely, in fawn hooded
rats (which develop spontaneous PH), FAO
is decreased (123). It is likely this disease
heterogeneity, which is relatively chamber
specific and primarily affecting the RV, is
also seen in humans; however, this has
not been systematically assessed. Other
metabolic pathways are induced in RVH as
well, including the de novo appearance of
cardiomyocyte glutaminolysis (although this
finding requires confirmation) (124). It is
unknown if a “point of no return” exists in
the transition from adaptive to maladaptive
RV remodeling and whether certain failure
components are more important than
others (117). For example, if impaired FAO
in cardiomyocytes is the root cause of
RVF, other processes (e.g., apoptosis,
inflammation, fibrosis) would be
downstream consequences, and therapeutic
interventions would need to aim at reversing
impaired FAO. Furthermore, it is unclear
whether inflammation, oxidative stress,
neurohormonal activation, or metabolic
alterations equally affect RV function in the
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acute versus chronic setting and whether
targeting these processes has the same
outcome in acute versus chronic RVF. The
role of hematological factors (e.g.,
hypercoagulation, platelet activation,
hypofibrinolysis) in initiating or propagating
acute (and possibly even chronic) RVF is
unknown. Furthermore, the contribution of
pulmonary vasoconstriction to inducing and
maintaining acute or chronic RVPO has not
been well defined. Last, the role of the LV in
the setting of RVPO needs further definition.
Even with acute PH, the LV becomes
compressed and stiffened by an enlarged
RV, thereby contributing to reduced CO
(102, 103).
Recommendations/pathway for
progress. Targets and pathways important
in acute RVF should be evaluated in chronic
RVF (and vice versa), allowing for
identification of common as well as unique
targets and pathways in either setting. For
example, in acute PE, hemolysis increases
shear forces in the RV (125), and multiple
sites in the coagulation cascade are believed
to contribute to acute RVF development
(126, 127). If these processes are identified
as being unique to acute RVF, their study
may lead to novel treatment targets. If a
role in chronic RVF is established, these
concepts could then be expanded to
treating the chronically failing RV.
Comparing acute with chronic RVF will
allow for a better understanding of the
transition from compensated RV
remodeling. Phenotypic, genetic, and
epigenetic determinants of adaptation in
the acute or chronic setting should be
studied. Comprehensive and integrated
systems biology/-omics approaches are
most likely to yield novel insights regarding
the shared and divergent pathways and
mechanisms between acute and chronic
RVF.
Regional Differences in RV
Responses
Rationale. Recent data indicate that RV
responses to acute or chronic afterload stress
vary between different regions of the RV.
Uncovering these regional differences will
help identity mechanisms of transition from
adaptive to maladaptive RVH. Please see the
online supplement for further details. LV
involvement in RV disease and ventricular
interdependence are covered in ASSESSMENT
OF RV–LV INTERACTIONS AND VENTRICULAR
INTERDEPENDENCE.
Table 3 lists key knowledge gaps and
solution approaches for topic domain 1.
Topic Domain 2: Analyzing
Advanced RV Hemodynamic
Parameters at Rest and in
Response to Exercise
Rationale
Identification of knowledge gaps and
solution approaches in hemodynamic
phenotyping and prognostication requires
a detailed understanding of the various
tools used. This section, therefore, reviews
strengths and weaknesses of commonly used
tools, identification of knowledge gaps, and
pathways for progress.
Invasive and Noninvasive
Phenotyping of RV Function
Current state of knowledge and knowledge
gaps. Comprehensive assessment of the RV
requires a combination of RHC and RV
imaging via echocardiography or CMR.
Biomarkers and exercise testing serve as
additional tools. RHC allows for a thorough
(though not complete) description of RV
function, with right atrial pressure to
estimate RV end-diastolic volume, or
preload, PAP, or PVR to estimate afterload,
and stroke volume (SV) to reflect
contractility. Imaging by echocardiography
and/or CMR offers additional information.
Both provide accurate (although sometimes
imprecise) estimates of systolic, mean, and
diastolic PAP, left atrial pressure (LAP), and
CO, and derived calculations of PVR and
pulmonary arterial (PA) compliance. More
importantly, both techniques provide
indices of RV systolic function, diastolic
function and filling pressures, planar and
volumetric estimations of dimensions,
and quantifications of dyssynchrony
(interregional inhomogeneity of
contraction) and asynchrony
(interventricular inhomogeneity of
contraction) and RV volumes.
Recommendations/pathway for
progress. RV function is often reported in a
cursory fashion and frequently limited to an
EF measurement. A physiologically sound
definition of RVF (see DEFINITION,
DEVELOPMENT, AND STAGING OF RVF) should
be implemented in biological and clinical
studies, to avoid ambiguity in bench-to-
bedside translation and epidemiology.
Clinical studies can achieve this through an
integrated imaging and invasive approach
(e.g., RHC, imaging by echocardiography
and/or CMR, and possibly PET [128]);
preclinical investigations should use
comprehensive hemodynamics and RV
imaging studies (70).
Prognostic Relevance of
Measurements of RV Function
Current state of knowledge and knowledge
gaps. Table E1 in the online supplement
provides an overview of the prognostic
capabilities of RHC-, echocardiography-,
and CMR-derived variables in various types
of severe PH. Various combinations of these
parameters have been used in prediction
models (129, 130). RHC-derived predictors
of outcomes include CO (measured or
calculated from mixed venous blood
oxygenation) (131–135), right atrial
pressure (132–134, 136), PVR (135–137),
and PAP (133). Echocardiographic
predictors include pericardial effusion
(138–141), right heart dimensions (139,
140, 142–144), estimated RV diastolic
pressure (140, 145), tricuspid regurgitation
(142), TAPSE (23, 140, 143, 146),
maximum tissue velocity of isovolumic
contraction (147), dP/dt (146), strain
(evaluated by variable and evolving
methodologies) (141, 148, 149), asynchrony
and regional inhomogeneity of RV
contraction (150), myocardial performance
index (151, 152), RV fractional area change
(130), right atrial size index (130), and RV
contractile reserve (defined as the exercise-
induced increase in the maximum velocity
of tricuspid regurgitation) (153). These data
suggest that echocardiography offers
prognostication via measurements of RV
systolic function (TAPSE, velocity of
isovolumic contraction, dP/dt, strain,
myocardial performance index, contractile
reserve), dimensions, and estimates of
filling pressures. CMR-derived predictors
include SV (21, 154), end-diastolic volume
(21, 155), RVEF (3, 154, 156), end-systolic
volume (ESV) (129, 157), SV/ESV (3),
and late gadolinium enhancement (158).
The latter, however, is not uniformly
confirmed (159). CMR therefore offers
prognostication from measures of systolic
function (ESV, EF, SV/ESV) and right heart
dimensions. A recent CMR-based study
used machine learning of patterns of RV
motion for outcome prediction in PH (160).
Because of their noninvasive nature, there
has been particular interest in using imaging
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parameters to assess RV function. The
current knowledge, knowledge gaps, and
potential future roles of commonly used RV
imaging parameters are listed in Table 4.
As of now, CMR remains the standard of
measurement, and RVEF is the most robustly
validated parameter. Head-to-head
comparisons of other imaging parameters
with regard to superiority are lacking, and
the appropriateness for use of one specific
parameter rather than others in special
clinical scenarios has not been well described.
Please see the online supplement for further
discussion of caveats pertinent to the use
of RV function markers as prognosticators.
Recommendations/pathway for
progress. Imaging or invasive
measurements of RV function, identified as
prognostic indicators in PAH, should be
evaluated together in the framework of a
multicenter trial and prediction scores
constructed from rigorously identified
independent predictors. A hierarchy
of imaging parameters and their
appropriateness for specific scenarios
should be determined.
Assessment of RV Afterload
Current state of knowledge and knowledge
gaps. With low-normal PVR, the
contribution of the RV to pulmonary blood
flow is modest at rest (evidenced after a
Fontan operation). However, RV pump
function is required in cases of increased
afterload (e.g., in acute or chronic PH). RV
afterload is affected by PVR, but there are
several other equally valid contributors (161):
1) Maximum wall tension (an impractical
parameter because of the irregular shape of
the RV and regional inhomogeneities in
contraction); 2) hydraulic power (WTOT;
calculated from the integration of
instantaneous pressure and flow waves,
which is the sum of oscillatory power
[WOSC] and steady power [WST =mPAP3
CO]); 3) arterial elastance (Ea; calculated
from an RV pressure–volume loop as
end-systolic pressure [ESP]/SV),
corresponding to a measurement of
afterload as “seen” by the ventricle; and
4) pulmonary vascular impedance, which
represents the most comprehensive
assessment of RV afterload (although least
accessible to the clinician) (162).
RV pressure–volume loops with
preload reduction allow for identification of
the end-systolic elastance (Ees; the standard
of measure for load-independent
contractility in vivo). Direct measurements
of Ees and Ea allow for calculation of the
Ees/Ea ratio as a measurement of the
coupling of the RV to the pulmonary
circulation (2, 161) (Figure 4). This concept
was initially developed for the LV (163) but
soon thereafter was shown to be applicable
to the RV (164). Sagawa and colleagues
demonstrated that optimal efficiency of
ventriculoarterial coupling (allowing for
flow output at minimal amount of energy
cost) is achieved in either ventricle when
maximal or end-systolic elastance is 1.5 to
2 times greater than Ea (165). In the RV,
the amount of uncoupling associated with
decreased maximum cardiac output and
increased RV size with high filling pressures
and systemic congestion is not exactly
known (128). Although a coupling ratio
of 1 at rest may still be associated with
preserved RV dimensions, at this level
of Ees/Ea, there is impaired contractile
reserve, and exercise is associated with
uncoupling and increased dimensions (166,
167). Furthermore, in experimental animal
models of embolic PH, the RV starts to
dilate when Ees/Ea is decreased to 0.7 to 1.0
(168, 169). Most investigators therefore
consider “optimal” mechanical RV–arterial
coupling to correspond to an Ees/Ea of 1 to
2. Interestingly, for a similar afterload,
patients with scleroderma-PAH demonstrate
lower Ees/Ea than patients with idiopathic
PAH (1.0 vs. 2.1) (170), suggesting
significant uncoupling in scleroderma-PAH.
Ea and WTOT are metrics of RV
afterload, so it is understandable that these
measurements of the pulmonary circulation
emerge as prognostic markers of RVF
in severe PH (171, 172). For example,
increased stiffness of the proximal PA,
mediated by excessive collagen accumulation,
increases the pulsatile component of RV
afterload (quantified by measurement of
impedance [173]) and thus decreases RV–PA
coupling and RV contractile reserve (defined
as the ability of the RV to increase contractile
function during exercise) (2, 153, 174).
Table 3. Key Knowledge Gaps and Approaches to Improve Methodology to Assess
Right Ventricular Function in Acute and Chronic Conditions in Preclinical Models,
Human Studies, and Clinical Trials
Key knowledge gaps
d What is the definition of “normal” and “abnormal” RV structure and function? How do
key demographic characteristics such as age, sex, race/ethnicity, and socioeconomic
status affect the definitions of “normal” and “abnormal”?
d How do aspects of RV development throughout the life span as well as cardiopulmonary
interactions under stress and in response to critical exposures affect the definition of
“normal” vs. “abnormal” RV function?
d What is the exact impact of existing and novel PAH therapies on RV function?
d Better animal and in vitromodels are needed that allow study of RV function in all groups
of PH.
d What are the mechanisms of RV dysfunction in acute PE and ARDS? Which
interventions improve RV function in these settings?
Solution approaches/pathways forward
d After the identification of a critical set of RV biomarkers, a joint global effort is needed to
replicate and validate prior findings and to determine effects of age, sex, race/ethnicity,
exercise, and other exposures on these biomarkers in animal studies and human
cohorts.
d Human RV specimens should be studied to improve understanding of human disease
and determine to what extent experimental models may or may not recapitulate human
disease.
d A small but unique set of biomarkers of RV function should be defined that can be used
to quantify load-independent effects of medical and nonmedical PH treatment in clinical
studies.
d While acknowledging that a single model reflecting RV function in all aspects and types
of PH is unlikely to be developed, novel models (in vivo, in vitro [e.g., “heart on a chip,”
iPSCs], and in silico) should be developed that replicate critical aspects of RVF in all
groups of PH.
d Determine mechanisms of RVF in patient cohorts and in animal models of acute (and
chronic) PE and ARDS. The effect of novel RV-directed therapies (e.g., prone positioning
in ARDS) on RV function in these settings should be prospectively studied.
Definition of abbreviations: ARDS = acute respiratory distress syndrome; iPSCs = induced pluripotent
stem cells; PAH = pulmonary arterial hypertension; PE = pulmonary embolism; PH = pulmonary
hypertension; RV = right ventricle; RVF = right ventricular failure.
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Table 4. Current State of Knowledge, Knowledge Gaps, and Potential Future Roles of Commonly Used Right Ventricular Imaging
Parameters
Imaging Parameter Current State
Disadvantages and
Knowledge Gaps Future Role
TAPSE d Easy and quick
assessment
d Less suitable for serial
assessment (284, 285)
d 2D measures will still be used
for assessment of RV function
d Cheap and widely available d 2D measures are less suitable
for serial assessment owing
to the complex geometry of
the RV
d High reproducibility (280,
281)
d Prognostic value at
baseline (23, 141, 282,
283)
RVFAC d Easy and quick
assessment
d Less reproducible than
TAPSE (280, 281, 285)
d See TAPSE
d Good relation with RVEF
(280, 285, 286)
d Less suitable for serial
assessment (285)
d Prognostic value at
baseline in PAH (141, 282,
283)
Eccentricity index d Easy and quick
assessment
d Lack of information on serial
assessment
d See TAPSE
d Prognostic value at
baseline in PAH (282, 283)
Strain/strain rate d Prognostic value in PAH
(141, 283, 287)
d Strain assessment possible
with echo (2D speckle
tracking) and CMR (tagging)
d Shows potential to assess RV
dysfunction in a very early
staged Early detection of RV
dysfunction; detects
differences in RV function
when other traditional
measurements, including
TAPSE, fail to do so (288)
d Tagging analyses
time-consuming
Myocardial performance
index (Tei index)
d No need to make
geometric assumptions
d Doppler echocardiography
only
d See TAPSE
d Prognostic value in PAH
(141, 282)
RVEF d Gold standard parameter
for assessment of RV
systolic function
d Assessment is
time-consuming
d Likely to be useful in
assessment of prognosis and
treatment response
d RVEF is reproducible (289)
d Presence of tricuspid
regurgitation can
overestimate RVEF
d Automated assessment of RV
volumes with CMR neededd Prognostic value at
baseline and during
follow-up (3, 21)
d Minimal clinical important
difference unknown
d 3D echocardiography may
enable accurate assessment;
however, currently 3D
echocardiography RV
underestimates volumes and
is less reproducible (290–294)
RVSV/RVESV d Prognostic value at
baseline (129, 184)
d Assessment time-consuming d May be an important
parameter, although the
measure shows a great
similarity to RVEF
d Minimal clinical important
difference unknown
d Reproducibility unknown
d Prognostic value of the
change over time unknown
d Indexing to body size may be
necessary but is not
consistently done
(Continued )
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Consequently, PA compliance is an
important predictor of mortality in PAH
(2, 172, 174, 175).
The most comprehensive measure
of RV afterload is pulmonary vascular
impedance, which represents the opposition
of the vascular bed to pulsatile flow generated
by friction in small-diameter vessels, stiff
vessels that do not accommodate pulsations,
and branching and tapering vessels that
generate wave reflections (162).
Recommendations/pathway for
progress. Contributions of the various
components of RV afterload to RV function
and RV adaptive and maladaptive processes
need better definition. Effects of PAH-targeted
therapies on components of RV afterload
require further study. Easy-to-obtain bedside
measures of RV afterload would be of value.
Assessment of RV–PA Coupling
Current state of knowledge and knowledge
gaps. The most accurate measurement of
RV–PA coupling is Ees/Ea. However, the
complex geometry of the RV makes
functional evaluations with measurement of
instantaneous volume changes technically
difficult. In addition, manipulating systemic
venous return to alter RV preload clinically
is not practical. Accordingly, a single-beat
method has been developed, allowing for
determining Ees and Ea from instantaneous
ventricular pressure and flow output (176)
or volume (129) measurements (Figure 4).
However, this method is controversial, as it
relies on multiple assumptions (176).
RV–PA coupling has been assessed in
several studies in patients with PAH or
CTEPH, and in one case report of a patient
with a systemic RV (129, 167, 170,
177–179). As shown in Table E2, Ees/Ea
was either maintained or decreased at rest
but consistently decreased at exercise. In
aggregate, these results agree with the
notion of homeometric adaptation of RV
function to afterload, even though the
results do not allow identification of critical
levels of decoupling associated with onset of
heterometric adaptation and congestion.
Recommendations/pathway for
progress. RV–PA coupling measurement
should be implemented in studies
investigating the mechanisms of action of
targeted therapies in PAH (which decrease
RV afterload but may or may not have
intrinsic myocardial effects), even if not as
the primary endpoint. It is controversial
Table 4. (Continued )
Imaging Parameter Current State
Disadvantages and
Knowledge Gaps Future Role
RV volumes d Prognostic value at
baseline and at change
during follow-up (3, 21,
157, 295)
d Assessment time-consuming d Will play a role for assessment
of prognosis and treatment
response
d Minimal clinical important
difference unknown (only
assessed for RVSV [20]) d Automated assessment of RV
volumes with CMR neededd Not consistently indexed to
body size d 3D echocardiography may
enable accurate assessment;
however, currently 3D
echocardiography RV
underestimates volumes and
is less reproducible in
comparison to CMR
(290–294)
LGE d LGE at interventricular
insertion points and
septum prognostic value
at baseline (159).
Possibility to assess
myocardial pathologies
(fibrosis) (296)
d MRI only d LGE will probably be replaced
by T1 mapping for
assessment of myocardial
pathologies in the future
d Need reference region of
interest in myocardium,
making LGE less suitable for
assessing diffuse myocardial
pathologies
Native T1 values d Native T1 values at
interventricular insertion
points are related to
measures of disease
severity (227, 297)
d MRI only d Shows potential to replace
LGEd Prognostic value unknown
d No administration of contrast
agents needed for generating
T1 maps
d Longitudinal changes
unknown
d More suitable for detection of
diffuse myocardial pathology
d Spatial resolution of T1 maps
currently too low to assess
total RV free wall (227)
d Future studies will need to
assess its prognostic value
d Resolution and correction for
partial volume effects (fat
saturation pulse) in T1
mapping needs to be
improved
Definition of abbreviations: 2D = two-dimensional; 3D = three-dimensional; CMR = cardiac magnetic resonance imaging; LGE = late gadolinium
enhancement; MRI =magnetic resonance imaging; PAH = pulmonary arterial hypertension; RV = right ventricular; RVEF = right ventricular ejection fraction;
RVESV= right ventricular end-systolic volume; RVFAC= right ventricular fractional area change; RVSV = right ventricular stroke volume; TAPSE = tricuspid
annular plane systolic excursion.
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whether Ees/Ea can be measured on a
single-beat pressure–volume loop versus
a family of such loops generated by a
manipulation of venous return. A study
comparing these methods in patients with
various types of PH is urgently needed.
Simplified surrogate measurements of
Ees/Ea, such as SV/ESP (156, 180) and (RV
maximum pressure/mPAP2 1) (181)
(Figure 4), should be validated.
Assessment of RV Diastolic Function
Current state of knowledge and knowledge
gaps. Coupling of RV function to afterload
has an inevitable diastolic component
(2, 161, 182). Diastolic stiffness may be a
predictor of outcomes in severe PH (183,
184). Please see the online supplement for a
summary of RV diastolic function
assessment.
RV diastolic function has not been
specifically explored by imaging studies.
Its description is generally limited to the
isovolumic relaxation time, the ratio of
trans-tricuspid flow E wave to tricuspid
annulus tissue Doppler imaging tricuspid e9,
the deceleration of the E wave, estimated
RV filling pressure from the inferior vena
cava dimension and inspiratory collapse,
and end-diastolic area or volume. However,
these measurements have not been
systematically confirmed with diastolic
pressure–volume curves or, with the
exception of occasional parameters (Table
E1), been considered as prognostic markers.
Recommendations/pathway for
progress. The relevance of RV diastolic
elastance or its surrogate, the end-diastolic
pressure–volume ratio, should be further
assessed. Novel, noninvasive measurement
techniques using echocardiographic or
other imaging methods are needed.
Assessment of RV–LV Interactions
and Ventricular Interdependence
Current state of knowledge and knowledge
gaps. RV function needs to be understood
in the context of its direct and indirect
interactions with LV function. Direct
interaction, or ventricular interdependence,
is defined as the forces that are transmitted
from one ventricle to the other through the
myocardium, perivalvular fibrous annulus,
and pericardium, independent of neural,
humoral, or circulatory effects (185).
Diastolic ventricular interaction refers to
the competition for space within the
indistensible pericardium when the RV
dilates. RHC and imaging studies
demonstrated that in patients with severe
PH, mPAP and LV peak filling rate are
altered in proportion to decreased RVEF
(186). Systolic interaction refers to
positive interaction between RV and LV
contractions. For example, aortic
constriction and the subsequent increase
in LV contraction markedly improve RV
function in animals with PAB (187).
Similarly, in electrically isolated ventricular
preparations, LV contraction contributes
significantly (z30%) to both RV
contraction and pulmonary flow (187). This
is explained by a mechanical entrainment
effect, but also by LV systolic function
determining systemic blood pressure (an
essential determinant of RV coronary
perfusion). This is important because increased
RV filling pressures and excessive decrease in
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Figure 4. Methods used to estimate right ventricle–pulmonary artery (RV–PA) coupling and diastolic
stiffness. In both (A) the volume method, and (B) the pressure method, arterial elastance (Ea) is
calculated from the ratio of end-systolic pressure (ESP) to stroke volume (SV). End-systolic elastance
(Ees) as an approximation of maximum elastance in the volume method is estimated by the ratio of
ESP to end-systolic volume (ESV), which results in a simplified Ees/Ea of SV/ESV. In the pressure
method, Pmax is estimated from the nonlinear extrapolation of the early systolic and diastolic portions
of the RV pressure curve. Ees is the ratio of (Pmax2mPAP) divided by SV, which results in a
simplified Ees/Ea of (Pmax/mPAP2 1). (C) The single-beat method calculates Ees as a straight line
drawn from Pmax tangent to RV pressure–relative change in volume relationship. The approach
relies on an estimate of Pmax determined from the extrapolation of early and late isovolumic portions
of an RV pressure curve and synchronized absolute or relative volume measurements. Ees is then
defined by a tangent from Pmax to the pressure–volume relationship, and Ea is defined by a line
drawn from the Ees point to end-diastolic volume (EDV) (at zero pressure). (D) Diastolic stiffness (b) is
calculated by fitting the nonlinear exponential P = a(eVb2 1) to pressure and volume measured at the
beginning of diastole (BDP, ESV) and the end of diastole (EDP, EDV). Adapted by permission from
Reference 184. BDP = beginning diastolic pressure; EDP = end-diastolic pressure; Evol = Ees
estimated by the volume method; mPAP =mean pulmonary arterial pressure; Pmax = RV maximum
pressure; sRVP = peak systolic RV pressure.
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blood pressure have been linked to RV
ischemia and decreased contractility (188).
An additional cause of negative
ventricular interaction is regional and
interventricular asynchrony with
postsystolic contraction or “shortening.”
This develops in parallel with increased
PAP and contributes to altered RV systolic
function and LV underfilling (189). RV
regional asynchrony can be identified and
quantified by echocardiography using two-
dimensional (2D) or 3D speckle tracking
(149, 156) (see REGIONAL DIFFERENCES
IN RV RESPONSES for further details).
Electrophysiologically, this phenomenon
is reflected by increased QRS width and
prolonged duration of the monophasic action
potential of RV myocytes secondary to
downregulation of repolarizing potassium
channels (72). Interestingly, this is amenable
to metabolic therapies (72). Likewise, QTc
duration increases in patients with PAH and
serves as a prognostic indicator that appears to
be related to RV mass (190). LV abnormalities
in patients with RVF are not limited to
functional changes. In fact, fibrotic and
inflammatory changes in LVs from patients
with PAH were recently reported (191).
Recommendations/pathway for
progress. Further insight into the functional
significance and clinical relevance of
dyssynchrony and asynchrony is needed.
Because interventricular interdependence
evolves in both acute and chronic RVF,
studies in relevant preclinical models
are needed to determine the relative
contribution of this pathogenic mechanism
in those conditions. Mechanisms of structural,
biochemical and molecular LV abnormalities
in patients with RVF require further study.
Emerging and Alternative Approaches
Please see the online supplement for a
detailed discussion of this topic.
Table 5 lists key knowledge gaps and
solution approaches for topic domain 2.
Topic Domain 3: Deciphering
the Underlying Molecular and
Pathogenic Mechanisms of
RV Function and Failure
Assessment of Hypertrophy and
Angiogenesis
Rationale. Adaptive myocardial remodeling
requires coordination of myocyte
hypertrophy and angiogenesis to preserve
ventricular function. Myocyte hypertrophy
associated with a disproportional number of
capillaries and/or endothelial cell (EC)
dysfunction may ultimately promote RVF.
Regulation of angiogenesis is complex
(reviewed in Reference 192) and involves
molecular cross-talk between myocytes and
ECs (193, 194). Insight regarding molecular
mechanisms linking RV myocyte
hypertrophy and angiogenesis is limited.
Further investigation is likely to identify
new paradigms and therapeutic strategies.
Current state of knowledge. In the LV,
angiogenesis is necessary (195, 196) and
sufficient (197, 198) for myocyte
hypertrophy. The interplay between
angiogenesis and myocyte hypertrophy is
poorly defined in the RV, which has unique
mechanisms to augment myocyte perfusion
during increased myocardial demand (199).
A detailed review of the topic was recently
published (200). RV angiogenesis has been
evaluated in animal models of PH, although
most studies relied on counting capillary
profiles in 2D sections. Some authors
believe that this approach may lead to
underestimation of effective capillary length
and surface area (201) and unintentional
sampling bias (201, 202) that may lead to
inconsistent findings, even within the same
model (203–208). Analysis of 2D sections
in PH models associated with RVF
demonstrated reduced RV capillary density
(65, 124, 207), potentially reflecting
capillary rarefaction. In the rat
monocrotaline model, early microvascular
expansion was reversed as RVF ensued
(209). These data, obtained from several
laboratories and consistent with data
reporting vascular rarefaction in LV
hypertrophy, suggest that a combination
of cardiomyocyte hypertrophy (causing
increased demand) and capillary
rarefaction leads to clinically relevant
RV ischemia in PAH (210). However, a
recent analysis of human RV tissue by
a stereological approach noted an
increase in total vascular length in PAH
Table 5. Key Knowledge Gaps and Solution Approaches for Analyzing Advanced Right
Ventricular Hemodynamic Parameters at Rest and in Response to Exercise
Key knowledge gaps
d What are the gold standard measurements of RV–arterial coupling (Ees/Ea) in various
types and severities of PH? What is their relevance to functional state, exercise
capacity, and outcomes?
d What is the natural history of RV–arterial uncoupling and RV dilatation/altered diastolic
function and congestion?
d How can simplified pressure and volume methods to estimate RV–arterial coupling be
validated?
d How can items on the currently growing list of echocardiographic and CMR
measurements of systolic and diastolic dimensions and function be integrated and
validated (e.g., what is the added value with respect to RHC)? Is there a need for
scores?
d What are optimal* measures of RV afterload (e.g., WTOT, Ea, PA compliance, Ca, Zc,
low-frequency PVZ, imaging of proximal stiffness, RV wall tension)?
d How can differences in definition, methodology (e.g., exercise, dobutamine) and
relevance of RV contractile reserve measurements be resolved and harmonized?
Solution approaches/pathways forward
d Perform further monocentric expert physiological and clinical studies on RV–arterial
function adaptation to PH using gold standard invasive methodology in various clinical
circumstances.
d Further definition of the best compromise between gold standard and simplified imaging
methods.
d Multicenter effort to investigate the hemodynamic, imaging, and CPET predictors of
functional capacity and survival.
d Implement optimal invasive and noninvasive phenotyping measures of RV function in
basic and human studies focusing on the biology of RVF.
Definition of abbreviations: Ca = capacitance; CMR= cardiac magnetic resonance imaging; CPET =
cardiopulmonary exercise testing; CTEPH = chronic thromboembolic pulmonary hypertension; Ea =
arterial elastance; Ees = end-systolic elastance; PA = pulmonary artery; PAH = pulmonary arterial
hypertension; PH = pulmonary hypertension; PVZ = pulmonary vascular impedance; RHC = right
heart catheterization; RV = right ventricular; RVF = right ventricular failure; WTOT = hydraulic power;
Zc = characteristic impedance.
*The group notes that one should not expect to find one optimal measure of RV afterload. Rather, one
measure may be better for diagnosis, and another may be better for prognosis; one may be better for
CTEPH and one for scleroderma-associated PAH; etc.
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RVs versus controls (211). Although the
role of microvascular ischemia is still
controversial, the role of macrovascular
ischemia (reduced coronary perfusion
pressure due to elevated RV end-diastolic
pressure) is established (188).
Molecular regulators of RV
angiogenesis and myocyte hypertrophy have
received limited attention. In addition,
whether molecular regulation is similar
between the failing LV and RV is also
incompletely understood. Animal models
support potential roles for hypoxia-
inducible factor and vascular endothelial
growth factor (65, 207, 209), although these
pathways may be impaired in RVF (64,
119). Recent studies identified additional
potential proangiogenic regulators in the
LV (e.g., PlGF, NF-kB [nuclear factor-kB],
extracellular ubiquitin, STAT3, Nrf2, and
Ang-2/Tie-2) (197, 212–216), but these
have not been studied in the RV. A potential
regulatory role for the proangiogenic
microRNA miR-126 in RV capillary
rarefaction was recently shown (217).
Although several angiostatic factors were
recently identified as unique biomarkers in
PAH (218, 219), their role in regulating RV
angiogenesis has not been explored.
Current knowledge gaps. Pivotal
questions are whether RV angiogenesis
is necessary for adaptive myocardial
remodeling and whether EC dysfunction,
insufficient angiogenesis, and/or capillary
rarefaction lead to maladaptive remodeling
and RVF. The quantitative and temporal
relationship between myocyte hypertrophy
and angiogenesis required to preserve RV
function in PH has not been established.
Better understanding of the molecular
regulators of RVH and angiogenesis is needed
to develop studies designed to investigate
whether hypertrophy and successful
adaptation depend on angiogenesis. The
potential role of angiostatic/antiangiogenic
factors (217, 218, 220) in counteracting
initial angiogenic responses is incompletely
understood. The applicability of any single
animal model to human RV angiogenesis
and hypertrophy in PH is uncertain, and
differences between models require further
characterization. Angiogenesis data from
patients with PAH are extremely limited,
and current noninvasive imaging modalities
lack sufficient resolution.
Recommendations/pathway for
progress. Studies focused on RV myocyte
hypertrophy and angiogenesis that use
standardized, quantitative metrics avoid
unintentional sampling bias and produce
physiologically relevant endpoints
(stereological methods [221]) that will
improve precision and significance of
morphometric studies. Mechanistic studies,
including both unbiased screens for
angiogenic and angiostatic mediators and
hypothesis-driven assessment of specific
regulatory candidates during multiple
stages of RV remodeling, will advance
the field. Additional insight is likely to
be gained by more advanced imaging
techniques (micro–computed tomography,
microsphere injection), although these will
require comprehensive assessment of the
entire RV or a rigorous, unbiased sampling
strategy.
Table 6 lists several key
recommendations for the study of
molecular and pathogenic mechanisms of
RV function, which are relevant for the
study of RVH and angiogenesis but are
also critical for the study of the other
mechanisms listed in topic domain 3. RV
vascularization should be measured in an
unbiased fashion; however, there currently
is no agreement on whether stereology is
the only acceptable technique for this. At
the very least, further studies are needed
that compare stereological versus other
techniques (e.g., two-photon confocal
imaging with 3D reconstructions). We
strongly recommend the inclusion of
human samples for morphological studies,
Table 6. Key Knowledge Gaps and Solution Approaches for Deciphering the
Underlying Molecular and Pathogenic Mechanisms of Right Ventricular Function and
Failure
Key knowledge gaps
d Is angiogenesis and/or capillary maintenance necessary to preserve RV function during
remodeling, and does capillary rarefaction cause maladaptive RV remodeling?
d Does myocardial fibrosis promote RVF, and can it be reversed?
d Are metabolic alterations necessary for transition from adaptive to maladaptive RV
remodeling? If so, which changes are the most important ones in this process? Which
alterations in myocardial metabolic pathways should be targeted therapeutically, and
how?
d Are apoptosis and other forms of cellular death necessary for transition from adaptive to
maladaptive RV remodeling?
d Are myocardial inflammation and oxidative stress causes or consequences of RVF?
d What is the role of circulating and resident progenitor cells in modulating RV
hypertrophy, angiogenesis, fibrosis, metabolism, cell death, inflammation, oxidative
stress, and contractile signaling?
d How do established and novel PAH therapies modulate RV hypertrophy, angiogenesis,
fibrosis, metabolism, cell death, inflammation, oxidative stress, and contractile
signaling?
d Are potential short-term detrimental effects on RV contractile function with
neurohormonal modulators (e.g., b-adrenergic receptor antagonists) offset by long-term
beneficial effects on other signaling pathways?
Solution approaches/pathways forward
d More human studies focused on identifying mechanisms of RVF and facilitated through
RV biopsy samples, tissue repositories, and development of advanced imaging
techniques. In order to enhance scientific impact, human subjects need to be well
phenotyped
d Identification and validation of biomarkers of RV remodeling and dysfunction to facilitate
human studies in PH-induced RV dysfunction
d Use of stereological methods in all morphometric analyses, including both human tissue
and animal models
d More studies investigating the roles of sex and age as modifiers of RV function
d More studies investigating the roles of circulating and resident progenitor cells as
modifiers of RV function
d Next-generation sequencing techniques in humans and animals to identify genetic
contributors to RV adaptation and maladaptation
d Correlation of findings from cellular and animal studies with human phenotypes
d Identification/clarification of important mechanistic differences between preclinical
models of RV adaptation and RVF
d Expanded use of RV working heart models and in vitro analyses of diverse myocardial
cell types to evaluate specific regulatory pathways
Definition of abbreviations: PAH = pulmonary arterial hypertension; PH = pulmonary hypertension;
RV = right ventricular; RVF = right ventricular failure.
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which may be facilitated by the
development of central tissue repositories.
RV biopsy is safe in patients with RVH at
the time of surgery (e.g., in pulmonary
endarterectomy for group 4 PH [222]). We
recommend that preclinical studies evaluate
hypertrophy and angiogenesis in multiple
models, including both male and female
subjects. Studies of sex and age as modifiers
of hypertrophy and angiogenesis should be
pursued to better understand these relevant
modulators of RV function (30, 36, 223).
The potential role of progenitor cells as
modifiers of RVH and angiogenesis (224)
requires further study. Next-generation
sequencing techniques in humans and
animals may help identify genetic
contributors to hypertrophy development
and angiogenesis. Development and
validation of noninvasive imaging
techniques with adequate resolution to
assess RV myocyte hypertrophy and
angiogenesis should be a priority.
Assessment of Fibrosis
Rationale. Fibrosis is a common end result
of various pathogenic processes (2, 119),
resulting in contractile dysfunction, diastolic
dysfunction, and arrhythmias (2, 119).
Cardiac fibrosis can be detected using CMR;
patients with PAH with late gadolinium
uptake (indicating fibrosis) have a poor
prognosis (158). Strategies aimed at
decreasing fibrosis may attenuate RVF.
Current state of knowledge. Major
mediators of fibrosis include angiotensin,
aldosterone, transforming growth factor-b,
and matrix metalloproteinases (119). In
preclinical studies, fibrosis is typically
quantified via histological methods (e.g.,
collagen staining with trichrome or
picrosirius red). More indirect measures
of fibrosis include hydroxyproline assays
and measurements of collagen breakdown
products in the urine. In clinical studies, the
gold standard for fibrosis assessment is
CMR with late gadolinium enhancement
(225, 226). Native T1 mapping by magnetic
resonance imaging (MRI) provides similar
information without administration of
gadolinium (227). A role for PET scans is
emerging (e.g., with radiolabeled cyclic
arginine-glycine-aspartic [RGD] peptides
tracking a-v b-3 integrin expression [228]).
Current knowledge gaps. The clinical
relevance of RV fibrosis in PAH is uncertain.
Although late gadolinium enhancement at
septal hinge points on CMR (corresponding
to areas of increased mechanical stress)
predicts increased mortality, findings of
fibrosis among autopsy series vary, and less
is known about patients with early disease.
No biomarkers of RV fibrosis currently
exist. The role of fibrosis in mediating
transition from adaptive to maladaptive RV
remodeling is unclear. Uncertainty exists
about the possible role of circulating
progenitor cells and resident progenitor cells
in mediating RV fibrosis. Conversely, a
better understanding of mechanisms
mediating regression of fibrosis is needed. It
is unclear how representative animal models
are of RV fibrosis, and differences between
models are not sufficiently characterized.
Finally, it is unknown if therapies targeting
RV inflammation, angiogenesis, and
bioenergetics (229) or PAH-directed
therapy will reduce RV fibrosis.
Recommendations/pathway for
progress. Noninvasive studies of RV fibrosis
and assessment of RV biopsy specimens will
improve understanding of the mechanisms
and consequences of RV fibrosis in human
RVF. The routine use of gadolinium-
enhanced CMR (already part of the
monitoring algorithm in many centers)
should be considered as a potential gold
standard for noninvasive detection and
quantification of RV fibrosis. Identification
and validation of potential biomarkers of
RV fibrosis would move the field forward.
The study of isolated fibroblasts from
normal and diseased RVs would provide
novel mechanistic insights in fibrosis
progression and regression. It will be
important to know whether disorders found
in pulmonary vascular cells and RV
cardiomyocytes are also detected in RV
cardiac fibroblasts. In vitro studies of
PH-RV fibroblasts should confirm that
these cells retain their disease phenotype
in cell culture. Table 6 lists further
recommendations regarding the study of
human samples, stereology, biomarkers,
progenitor cells, consideration of sex and
age, and use of next-generation sequencing
techniques.
Assessment of Cardiomyocyte
Metabolism
Rationale. The normal adult RV relies
primarily on primary FAO for ATP
production (230). However, metabolic
plasticity in the RV is seen at the time of
birth and with disease states inducing RVH.
RV myocytes engage in several maladaptive
forms of metabolism during hypertrophy,
including uncoupled glycolysis,
dysregulated FAO, and glutaminolysis
(reviewed in Reference 229). Because these
alterations contribute to cardiomyocyte
dysfunction (69, 72, 122, 231, 232), further
insight into mechanisms of metabolic
dysregulation is likely to identify new
paradigms and new targets for therapeutic
intervention.
Current state of knowledge. RV
myocardial energetics are implicated in the
regulation of RV function in experimental
and clinical PAH, and metabolic therapies
are well validated in preclinical models (65,
69, 72, 122, 231, 232). Metabolic changes
may be (in part) elicited by ischemia
and potentially genetic and epigenetic
alterations (69, 233, 234). Epigenetic
changes may be mediated by histone
deacetylation, methylation of CpG islands
(promoter regions with a high frequency of
C-phosphate-G nucleotides), and miRNAs.
Fluorodeoxyglucose F 18–PET studies have
shed light on metabolism in humans,
suggesting PAH-associated RVH is
associated with increased glucose uptake.
There are early, conflicting data regarding
changes in FAO in the PAH-RV (235–239).
Clinical trials are currently evaluating
whether correction of metabolic alterations,
such as reducing FAO or enhancing glucose
oxidation, attenuates RVF (Clinicaltrials.
gov identifiers NCT02102672 and
NCT01083524).
Current knowledge gaps. Gaps exist in
understanding the contribution of metabolic
dysfunction to RVF, in particular the
metabolic processes that drive transition
from RV compensation to failure. Defining
which metabolic changes are considered
adaptive versus maladaptive will assist in
testing metabolic therapies to prolong RV
compensation and improve outcomes.
Triggers of altered metabolism in the human
RV, and whether correction of ischemia
would reverse RV metabolic dysfunction,
remain unknown. Moreover, it is unclear
whether RV ECs or fibroblasts exhibit similar
metabolic abnormalities to myocytes.
Recommendations/pathway for
progress. Additional study of metabolic
dysregulation in humans and human tissues
is needed. Use of micropolarimetry would
allow for direct measurement of metabolism
in freshly isolated RV myocytes (reviewed
in Reference 229). Such direct ex vivo
studies, as well as use of in vivo confocal
microscopy, would be important to avoid
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pharmacological inference from in vivo
experiments as a basis for defining changes
in the RV in PH. Metabolic imaging, using
PET with conventional and novel
radiotracers and MR spectroscopy, holds
promise to enhance understanding of the
in vivo metabolic RV phenotypes and
defining the transition from compensation
to decompensation. In preclinical studies,
use of Langendorff and working heart
models allows more definitive attribution
of metabolic therapies to changes in RV
function. In vivo, the use of high-fidelity
catheters to measure pressure–volume
relationships can help establish effects of
metabolic therapies on the RV (240).
Metabolic studies in skeletal muscle may
be highly relevant in patients with PAH,
because several metabolic abnormalities
are also evident peripherally (241–243).
Human samples, stereology, biomarkers,
progenitor cells, sex and age, and
sequencing techniques should be
considered as outlined in Table 6.
Assessment of Cell Death
Rationale. Cardiomyocyte death is
considered the common end result of
various pathogenically relevant processes
(e.g., ischemia, neurohormonal activation,
inflammation, oxidative/nitrosative stress,
mechanical stress, pressure overload) (2,
119). Consequences of cardiomyocyte death
include fibrosis, contractile and diastolic
dysfunction, and potentially arrhythmias
(2, 119). Strategies aimed at decreasing
cardiomyocyte death may prevent the
transition from adaptive to maladaptive
remodeling and may improve outcomes
in RVF.
Current state of knowledge. The
predominant type of cell death in the RV
is considered to be apoptotic, affecting
predominantly the cardiomyocyte (2, 119).
Troponin levels are currently used for
markers of myocyte damage and death
(244). Apoptosis is assessed in animal
studies by measuring abundance or activity
of proapoptotic pathways (e.g., bax,
caspase-3), terminal deoxynucleotidyl
transferase dUTP nick-end labeling, and
quantification of annexin V expression. In
clinical studies, cell death is assessed indirectly
via CMR or PET–computed tomography
(using annexin-based probes) (225).
Current knowledge gaps. The role of
cell death in RV cell types other than
cardiomyocytes (e.g., cardiac ECs) remains
unknown. Furthermore, the contribution
of nonapoptotic types of cell death (e.g.,
autophagy, necroptosis [245–248]) is poorly
defined. Uncertainty exists about the
possible role of circulating progenitor cells
and resident progenitor cells in modifying
RV cell survival and death. The potential
contributions of endoplasmic reticulum
stress, mitophagy, as well as genetic and
epigenetic contributors to RV cell death are
unknown. Furthermore, the role of cell
death in mediating transition from adaptive
to maladaptive RV remodeling is unclear.
Little is still known about the relevance of
RV cell death in patients with PAH, as
findings in autopsy series vary and are
usually limited to patients with end-stage
disease. It is unclear how representative
animal models are of RV cell death, and
differences between models have not been
sufficiently characterized. Last, a better
understanding of established and novel
PAH therapies on RV cell death is needed.
Recommendations/pathway for
progress. The role of cardiomyocyte or
cardiac EC death as a driver from adaptive to
maladaptive RV remodeling needs further
study. In particular, moremechanistic studies
in animal models and isolated RV cells
focusing on initiators and modifiers of cell
death of cardiomyocytes and other relevant
cell types (e.g., cardiac ECs) and correlation
of findings with human phenotypes will
provide a better understanding of
mechanisms of RV cell death. Studies of
isolated cardiomyocytes and ECs (ideally
from animal models of severe RVF and/or
well-phenotyped human samples) would
provide novel mechanistic insights in RV cell
death initiation and progression. The
contribution of endoplasmic reticulum stress,
mitochondrial fusion and mitophagy (249),
autophagy (245–247), and nonapoptotic
types of cell death to RVF development
requires further study. Identification and
validation of cardiac troponins as markers of
cardiomyocyte death (rather than damage)
would move the field forward. Identification
of novel targets and probes for apoptosis and
cell death imaging will help study cell death
in animals and in humans. Strategies and
regulators listed in Table 6 also apply to the
study of RV cell death.
Assessment of Inflammation
Rationale. Inflammation is an integral
contributor to the development of both
acute and chronic RVF (2, 95, 119, 229,
250). Strategies aimed at decreasing RV
inflammation may prevent or delay the
progression from adaptive to maladaptive
RV remodeling and result in improved
outcomes. Monitoring RV inflammation
may serve as a “biomarker” of RV function
and/or treatment responses.
Current state of knowledge.
Inflammation, among other processes,
likely contributes to RV fibrosis and
contractile dysfunction. Influx of
inflammatory cells and expression of
proinflammatory cytokines and adhesion
molecules is observed rapidly (within 2 h)
after onset of RVPO (96, 98, 250).
For example, in animal models of PE,
an influx of neutrophils and M1
macrophages is seen in the RV outflow
tract within 18 hours (95, 98, 250). On the
other hand, 6 weeks after acute RVPO,
secretory M2 macrophages predominate,
likely contributing to RV repair processes
(95). In chronic RVPO, abundant
expression of proinflammatory cytokines
is noted (223), although the degree of
inflammation appears to be less in
chronic RVF than in RVF from acute
RVPO (96).
Current knowledge gaps. Whether
inflammation is a cause or a consequence
of RVF is unknown. Initiators of RV
inflammation (e.g., ischemia, apoptosis,
impaired efferocytosis, mitochondrial
dysfunction, oxidative stress), and potential
links between inflammation and fibrosis,
apoptosis, and metabolic dysfunction need
to be identified. Similarly, it is unknown
whether a certain degree of inflammation
is beneficial for repair (and if so, how
much). In LV failure, distinct macrophage
populations have been linked to adaptive
and maladaptive responses (251); it is
unclear whether such a dual macrophage
function also plays a role in RVF. Detailed
investigation in human RVs (especially
from patients not in end-stage disease) are
lacking. Mechanisms mediating regression
of inflammation, and whether this
translates into clinical improvement,
are poorly understood. Last, a better
understanding of effects of established and
novel PAH therapies as well as specific
antiinflammatory strategies (e.g., ketorolac
[250]) on acute and chronic RV
inflammation is needed.
Recommendations/pathway for
progress. Further characterization of
inflammatory processes in the RV using
biopsy (222) and novel imaging
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approaches (225) targeting specific
inflammatory mediators in various stages
of RVF and in distinct PAH populations
(e.g., idiopathic vs. scleroderma-
associated) would provide a better
understanding of the role of inflammation
in RVF. Preclinical mechanistic loss- or
gain-of-function studies focused on
individual cell types, mediators, and
signaling pathways would provide a better
understanding of the inflammatory
contribution to RVF. Studying isolated
cardiomyocytes and other relevant cell
types (e.g., cardiac ECs and fibroblasts)
will provide novel mechanistic insights
into inflammatory signaling, especially
if the proinflammatory environment
of the failing RV can be recapitulated
in vitro. Identification of mediators of
inflammation development and regression
and correlation of findings with human
phenotypes will provide a better
understanding of mechanisms of RV
inflammation. Human samples, stereology,
biomarkers, progenitor cells, sex and age,
and sequencing techniques should be
studied as outlined in Table 6.
Assessment of Oxidative Stress
Rationale. Oxidative stress is a purported
contributor to RV dysfunction, providing
a strong rationale for studying the
oxidant/antioxidant imbalance of the
stressed myocardium in both acute and
chronically failing RV tissue. Please see the
online supplement for detailed discussion
of this topic.
Assessment of Contractile Signaling
and Calcium Handling
Rationale. The RV in PAH is
characterized by hypertrophy and both
systolic and diastolic dysfunction (182).
Perturbations in calcium handling have
been implicated in all of these processes.
A better understanding of calcium
signaling in the failing RV may lead to
novel diagnostic and/or therapeutic
interventions.
Current state of knowledge. The RV in
PAH exhibits changes in both the passive
and active portions of the contractile
apparatus. Sarcomere stiffening was
identified in isolated RV cardiomyocytes
(182). Both increased collagen
accumulation and intrinsic stiffening of RV
cardiomyocyte sarcomeres contribute
to RV myocardial stiffness. In mild
RVF, increased myofibril stiffness
predominantly contributes to myocardial
stiffening, whereas in severe RVF, both
myofibril- and fibrosis (collagen)-
mediated stiffness contribute to increased
RV myocardial stiffness (252). Sarcomere
stiffening and RV diastolic dysfunction is
caused by titin hypophosphorylation
(182). In addition, there is dysfunction of
active contractile regulator mechanisms.
Downregulation of SERCA2a
(sarcoplasmic reticulum Ca21-ATPase 2a)
appears to play a critical role in the
pulmonary vasculature in PAH (253).
Although less is known about calcium
handling in RV myocytes, recent data
from a pig pulmonary vein banding model
demonstrated downregulation of
SERCA2a and endoplasmic reticulum
stress (88). In a recent study, intracellular
calcium recycling appeared similar to
normal LVs in patients with idiopathic
PAH but was depressed in patients with
scleroderma-PAH (167). A follow-up
study using skinned cardiomyocytes
obtained from RV biopsies revealed
significant sarcomere dysfunction in
patients in scleroderma-PAH (254).
Apelin, a potent proangiogenic and
procontractile peptide that exerts critical
effects in the LV (255), may also be of
importance in the RV (223, 256).
Current knowledge gaps. More insight
is needed regarding mechanisms of calcium
homeostasis in the RV myocyte. The
occurrence, timing, and pathologic
relevance of changes in SERCA2a during
RVH in PAH is unknown. Although
selective pulmonary SERCA2a gene transfer
may offer benefit as a therapeutic
intervention for the vascular bed in PAH
(253), it is unknown if cardiac-targeted
SERCA2a therapy, an approach that was
(so far, unsuccessfully) taken to treat
patients with LV failure (257), would
be beneficial for the RV. The role of
mitochondrial calcium handling has
not been assessed in RVF; this may be
important, as the influx of calcium via the
mitochondrial calcium uniporter is a major
regulator of both cytosolic calcium and the
intramitochondrial calcium stores, which
regulate key enzymes in oxidative
metabolism (258). Effects of
neurohormonal modulators (e.g., inhibitors
of the renin-angiotensin/aldosterone
system) and b-adrenergic receptor
antagonists on RV contractile function
require further study. In particular, the
effect of the latter is of great interest,
because currently available studies yielded
conflicting results of these drugs on clinical
outcomes and RV function (259–263). RV
inotropic agents may improve short-
and/or long-term outcomes in acute and/or
chronic PH, but their role (and potential for
adverse events) is incompletely explored.
Recommendations/pathway for
progress. More studies of the
mitochondrial calcium uniporter and
sarcoplasmic reticulum calcium handling
system in preclinical models and humans
are required. Studies of active and passive
mechanisms that control RV diastolic and
systolic function likely will identify new
insights. In addition to addressing changes
in fibrosis (which determines passive
stiffness), more study of calcium pumps,
gap junctions, and ion channels (which
determine active stiffness) in RV myocytes
is required. More studies focusing on
the regulation of SERCA2a in RVF are
needed. Acute and chronic effects of
Table 7. Research Priorities to Be Addressed in the Next 5 Years
1. Understand the mechanisms underlying adaptive vs. maladaptive RV adaptation to
pulmonary vascular load, including role of fibrosis, angiogenesis, metabolic shifts
2. Develop a series of plasma and/or imaging biomarkers (by echocardiography and CMR)
that could be used to accurately evaluate RV function, perfusion, and RV–PA coupling
and as endpoints in clinical trials
3. Develop and validate or improve on current animal models of RV dysfunction in the setting
of increased pulmonary vascular load
4. Develop therapies aimed at targeting RV myocardial contractility (e.g., calcium-sensitizing
agents targeting sarcoplasmic reticulum and/or sarcomere function)
Definition of abbreviations: CMR= cardiac magnetic resonance imaging; PA = pulmonary artery; RV =
right ventricular.
The list was generated by surveying working group members to identify their top five priorities. The
most commonly mentioned topics and themes are included in the table.
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renin-angiotensin/aldosterone system
inhibitors and b-blockers on RV
contractile function require further study.
The role of therapies aimed at enhancing
RV myocardial contractility (e.g., apelin
and calcium-sensitizing agents) needs to
be explored in preclinical and clinical
studies. Studies in skinned RV
cardiomyocytes may allow for deciphering
mechanisms of RV dysfunction and
guide targeted therapies. General
recommendations from Table 6 also
pertain to the study of calcium and
contractile signaling.
Conclusions
This research statement delineates
areas of established knowledge in the
field of RVF, identifies and prioritizes
the most pertinent research gaps
(Table 7), and provides a prioritized
pathway for addressing these preclinical
and clinical questions. By combining
basic, translational, and clinical
approaches in an integrative and
multidisciplinary manner, investigators
will be able to further advance the
state of knowledge, with the ultimate
goal of developing RV-targeted
therapies for patients with RVF of any
etiology. Such therapies are anticipated to
prevent or reverse the progression from
adaptive to maladaptive RV
remodeling. n
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